OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RYTM
Rhythm Pharmaceuticals, Inc.
There isn't enough reported data to score RYTM yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RYTM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RYTM's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RYTM PE Valuation
RYTM has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RYTM on the outlook, with more favorable earnings expectations.
RYTM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RYTM's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RYTM on earnings quality, reporting a profit while its opponent remains loss making.
RYTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.90 | +$0.19 |
| Q2 2026 | -$3.11 | -$0.11 |
| Q1 2026 | -$3.13 | -$0.33 |
| Q4 2025 | -$3.11 | +$1.23 |
| Q3 2025 | -$3.09 | +$1.24 |
| Q2 2025 | -$3.00 | +$1.36 |
| Q1 2025 | -$2.80 | +$1.83 |
| Q4 2024 | -$4.34 | -$1.14 |
RYTM is still losing money, but less than at its worst: $2.90 per share over the past year, against $4.63 at its worst in early 2024.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RYTM on profitability, with a higher operating margin.
RYTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.1M | +80% |
| Q2 2026 | $71.3M | +47% |
| Q1 2026 | $60.1M | +84% |
| Q4 2025 | $57.3M | +37% |
| Q3 2025 | $51.3M | +54% |
| Q2 2025 | $48.5M | +67% |
| Q1 2025 | $32.7M | +26% |
| Q4 2024 | $41.8M | +73% |
RYTM has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -43% | +60 points |
| Q2 2026 | -68% | +25 points |
| Q1 2026 | -87% | +57 points |
| Q4 2025 | -82% | +16 points |
| Q3 2025 | -103% | +29 points |
| Q2 2025 | -93% | +46 points |
| Q1 2025 | -144% | +395 points |
| Q4 2024 | -99% | +72 points |
RYTM's operating margin was −43% last quarter, up 60 points from the same quarter a year ago, near the top of its range since 2021.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with RYTM at up 30%.
RYTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.2M | +$14.2M |
| Q1 2026 | -$44.2M | -$3.8M |
| Q4 2023 | -$29.4M | +$4.6M |
| Q3 2023 | -$29.3M | +$17.8M |
| Q2 2023 | -$41.1M | -$2.2M |
| Q1 2023 | -$36.5M | +$17.3M |
| Q4 2022 | -$34M | +$6.5M |
| Q3 2022 | -$47.1M | -$6.8M |
RYTM has burned cash in almost every quarter: −$103M over the past year, against −$140M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RYTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +453K shares |
| 1 year | +4.2% | +2.8M shares |
| 3 years | +19% | +11.2M shares |
| 5 years | +37% | +18.8M shares |
| Available history | +90% | +32.6M shares |
RYTM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RYTM Net Leverage
RYTM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RYTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.9 | Neutral |
| Stochastic | 58.5 | Neutral |
RYTM's weekly RSI is 58 (neutral) and its Stochastic is 58 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RYTM PE vs Healthcare Sector
RYTM has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
RYTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $96.6 | 14% above |
| 20 week MA | $102.8 | 6.8% above |
| 50 week MA | $98.3 | 12% above |
| 100 week MA | $87.0 | 26% above |
| 200 week MA | $61.1 | 80% above |
RYTM is in an uptrend: it's above all five of its weekly moving averages, and 80% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RYTM on returns for 2026, with the stronger performance.
RYTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.0 | $29.0 | +26% |
| 2021 | $29.0 | $12.2 | -58% |
| 2022 | $12.2 | $29.2 | +139% |
| 2023 | $29.2 | $46.0 | +57% |
| 2024 | $46.0 | $55.6 | +21% |
| 2025 | $55.6 | $110.0 | +98% |
| 2026 YTD | $110.0 | $109.9 | -0.1% |
RYTM's yearly returns have swung widely, from +139% in 2022 to −58% in 2021. It's roughly flat so far in 2026.